324 related articles for article (PubMed ID: 37466702)
1. Ligand-based active targeting strategies for cancer theranostics.
Bandyopadhyay A; Das T; Nandy S; Sahib S; Preetam S; Gopalakrishnan AV; Dey A
Naunyn Schmiedebergs Arch Pharmacol; 2023 Dec; 396(12):3417-3441. PubMed ID: 37466702
[TBL] [Abstract][Full Text] [Related]
2. Nanocarrier-Based Therapeutics and Theranostics Drug Delivery Systems for Next Generation of Liver Cancer Nanodrug Modalities.
Ruman U; Fakurazi S; Masarudin MJ; Hussein MZ
Int J Nanomedicine; 2020; 15():1437-1456. PubMed ID: 32184597
[TBL] [Abstract][Full Text] [Related]
3. Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance.
Bar-Zeev M; Livney YD; Assaraf YG
Drug Resist Updat; 2017 Mar; 31():15-30. PubMed ID: 28867241
[TBL] [Abstract][Full Text] [Related]
4. Receptor-Targeted Surface-Engineered Nanomaterials for Breast Cancer Imaging and Theranostic Applications.
Ahmad J; Rizwanullah M; Suthar T; Albarqi HA; Ahmad MZ; Vuddanda PR; Khan MA; Jain K
Crit Rev Ther Drug Carrier Syst; 2022; 39(6):1-44. PubMed ID: 35997100
[TBL] [Abstract][Full Text] [Related]
5. A comprehensive review on immuno-nanomedicine for breast cancer therapy: Technical challenges and troubleshooting measures.
Saravanakumar K; Anbazhagan S; Pujani Usliyanage J; Vishven Naveen K; Wijesinghe U; Xiaowen H; Vishnu Priya V; Thiripuranathar G; Wang MH
Int Immunopharmacol; 2022 Feb; 103():108433. PubMed ID: 34922248
[TBL] [Abstract][Full Text] [Related]
6. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
7. Tumor-targeted nanomedicines for cancer theranostics.
Arranja AG; Pathak V; Lammers T; Shi Y
Pharmacol Res; 2017 Jan; 115():87-95. PubMed ID: 27865762
[TBL] [Abstract][Full Text] [Related]
8. Receptor-based targeting of engineered nanocarrier against solid tumors: Recent progress and challenges ahead.
Akhter MH; Beg S; Tarique M; Malik A; Afaq S; Choudhry H; Hosawi S
Biochim Biophys Acta Gen Subj; 2021 Feb; 1865(2):129777. PubMed ID: 33130062
[TBL] [Abstract][Full Text] [Related]
9. Ligand conjugated lipid-based nanocarriers for cancer theranostics.
Kumar R; Dkhar DS; Kumari R; Divya ; Mahapatra S; Srivastava A; Dubey VK; Chandra P
Biotechnol Bioeng; 2022 Nov; 119(11):3022-3043. PubMed ID: 35950676
[TBL] [Abstract][Full Text] [Related]
10. Ligand-targeted theranostic nanomedicines against cancer.
Yao VJ; D'Angelo S; Butler KS; Theron C; Smith TL; Marchiò S; Gelovani JG; Sidman RL; Dobroff AS; Brinker CJ; Bradbury ARM; Arap W; Pasqualini R
J Control Release; 2016 Oct; 240():267-286. PubMed ID: 26772878
[TBL] [Abstract][Full Text] [Related]
11. Advancement in design of nanostructured lipid carriers for cancer targeting and theranostic application.
Rizwanullah M; Ahmad MZ; Garg A; Ahmad J
Biochim Biophys Acta Gen Subj; 2021 Sep; 1865(9):129936. PubMed ID: 34058266
[TBL] [Abstract][Full Text] [Related]
12. Nanomedicines functionalized with anti-EGFR ligands for active targeting in cancer therapy: Biological strategy, design and quality control.
Nguyen PV; Allard-Vannier E; Chourpa I; Hervé-Aubert K
Int J Pharm; 2021 Aug; 605():120795. PubMed ID: 34119579
[TBL] [Abstract][Full Text] [Related]
13. Ligand decorated biodegradable nanomedicine in the treatment of cancer.
Ahmad E; Ali A; Fatima MT; Nimisha ; Apurva ; Kumar A; Sumi MP; Sattar RSA; Mahajan B; Saluja SS
Pharmacol Res; 2021 May; 167():105544. PubMed ID: 33722711
[TBL] [Abstract][Full Text] [Related]
14. Active targeting strategy in nanomedicines using anti-EGFR ligands - A promising approach for cancer therapy and diagnosis.
Nguyen PV; Hervé-Aubert K; Chourpa I; Allard-Vannier E
Int J Pharm; 2021 Nov; 609():121134. PubMed ID: 34571073
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive approach of hybrid nanoplatforms in drug delivery and theranostics to combat cancer.
Thorat ND; Townley HE; Patil RM; Tofail SAM; Bauer J
Drug Discov Today; 2020 Jul; 25(7):1245-1252. PubMed ID: 32371139
[TBL] [Abstract][Full Text] [Related]
16. Ligand-targeted particulate nanomedicines undergoing clinical evaluation: current status.
van der Meel R; Vehmeijer LJ; Kok RJ; Storm G; van Gaal EV
Adv Drug Deliv Rev; 2013 Oct; 65(10):1284-98. PubMed ID: 24018362
[TBL] [Abstract][Full Text] [Related]
17. Design of Targeted Nanostructured Coordination Polymers (NCPs) for Cancer Therapy.
Novio F
Molecules; 2020 Jul; 25(15):. PubMed ID: 32751178
[TBL] [Abstract][Full Text] [Related]
18. [The development of novel tumor targeting delivery strategy].
Gao HL; Jiang XG
Yao Xue Xue Bao; 2016 Feb; 51(2):272-80. PubMed ID: 29856581
[TBL] [Abstract][Full Text] [Related]
19. Role of integrated cancer nanomedicine in overcoming drug resistance.
Iyer AK; Singh A; Ganta S; Amiji MM
Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1784-802. PubMed ID: 23880506
[TBL] [Abstract][Full Text] [Related]
20. Theranostic Nanomedicine; A Next Generation Platform for Cancer Diagnosis and Therapy.
Sharma R; Mody N; Agrawal U; Vyas SP
Mini Rev Med Chem; 2017; 17(18):1746-1757. PubMed ID: 26891932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
